Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings FREMONT, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based...

Quark Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery FREMONT, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based...